Financial Performance - Cash and cash equivalents were $65.5 million as of March 31, 2025, expected to fund operations into the second half of 2026[8] - Research and development expenses decreased to $7.1 million for Q1 2025 from $9.8 million in Q1 2024, a reduction of $2.7 million[8] - General and administrative expenses remained stable at $5.1 million for Q1 2025, compared to $5.0 million in Q1 2024[8] - Net loss for Q1 2025 was $(11.0) million, or $(0.90) per share, compared to a net income of $1.0 million, or $1.03 per share, in Q1 2024[8] - Total operating expenses for Q1 2025 were $12.2 million, down from $14.8 million in Q1 2024[15] Clinical Trials and Development - The first patient was dosed in Part B of the SIGNAL-AA Phase 2a clinical trial, with topline data readout expected in the first half of 2026[4] - Fast Track designation was granted to bempikibart for the treatment of alopecia areata, facilitating expedited development and review[3] - The SIGNAL-AA Phase 2a clinical trial demonstrated clinically meaningful activity in a difficult-to-treat patient population, with a median follow-up of 41 weeks showing maintenance of response[4][5] - The company is advancing bempikibart, a fully human anti-IL-7Rα antibody, targeting the treatment of alopecia areata[7] - Q32 Bio expects to report topline results from the SIGNAL-AA Part B trial in the first half of 2026, pending review of the results[4]
Homology(FIXX) - 2025 Q1 - Quarterly Results